Commonwealth Equity Services LLC Reduces Holdings in CRISPR Therapeutics AG: Understanding the Business Reality

Commonwealth Equity Services LLC, a reputable and renowned financial service provider, has recently announced a significant reduction in its holdings of CRISPR Therapeutics AG. In the 4th quarter of last year, the firm reportedly sold 56,244 shares of CRISPR Therapeutics stock, resulting in a 52.4% decrease in its overall holdings. As per the latest SEC filing, Commonwealth Equity Services LLC now owns a meager 0.07% worth of equities in the company, which currently translates to $2,076,000.

However, despite this significant development, there is no reason for shareholders to panic as investing always comes with its fair share of ups and downs. Moreover, when analyzing CRISPR Therapeutics’ quarterly earnings for this year’s first quarter against last year’s corresponding period and its connection to Commonwealth Equity Services LLC’s recent move will help us analyze things better.

During the first quarter of this year (May 8th), CRISPR Therapeutics reported that it had earned ($0.67) per share. Analysts were predicting something worse with an estimate set at ($1.64) per share; thus, beating expectations by $0.97 is undoubtedly significant news for any investor interested in gaining shares in this unicorn company.

Although it may seem like negative net margins are an issue for companies operating within today’s market structures such as those seen by CRISPR Therapeutics at 54,271.70%, analysis have shown that their operations more than make up for these supposed losses regarding revenue flows generated by their offerings.

CRISPR Therapeutics is using ground-breaking gene-editing technology known as CRISPR/Cas9 to develop revolutionary gene-based therapies targeting serious illnesses across broad disease areas such as oncology, regenerative medicine & rare diseases; we can see why companies like Commonwealth Equity Services LLC would be interested in investing in them further given their research portfolio’s extensive breadth.

In conclusion, a reduction in shares percentage for any company investment is not necessarily atypical. However, analyzing said data within the business reality may reveal a much more comprehensive understanding of the situation that could give investors reassurance or pause when considering top-performing companies such as CRISPR Therapeutics.

CRSP

Updated on: 18/05/2023

Financial Health

Neutral



Debt to equity ratio:


Price to earnings ratio:


Price to book ratio:

Show more

Price Target

Current $0.00

Concensus $0.00


Low $0.00

Median $0.00

High $0.00

Show more

Social Sentiments

We did not find social sentiment data for this stock

Analyst Ratings

There are no analysts data to display

Swiss Gene-Editing Company CRISPR Therapeutics Sees Increase in Institutional Investor and Hedge Fund Stakes


CRISPR Therapeutics, the Swiss gene-editing company that is dedicated to developing revolutionary gene-based medicines using its proprietary CRISPR/Cas9 platform, has recently seen institutional investors and hedge funds increase their stakes in the company. EverSource Wealth Advisors LLC soared by 2,440.0% in the third quarter alone; Whittier Trust Co. increased its position by 224%; HM Payson & Co. saw its position rise 104.2%, while Hollencrest Capital Management acquired a new position in CRISPR Therapeutics last quarter valued at approximately $25,000, and Wipfli Financial Advisors LLC also made a new acquisition of the stock worth $41,000.

The company’s remarkable CRISPR/Cas9 technology allows for precise and directed changes to genomic DNA for a broad range of disease areas such as hemoglobinopathies, oncology, regenerative medicine and rare diseases. The firm has established an extensive portfolio of therapeutic programs as it focuses on transforming gene-based medicines for serious diseases with clinical candidates targeting initially genetic blindness (CTX001 for β-thalassemia) and hemophilia A/B.

While insiders have sold 75,000 shares of the company’s stock valued at $3,584,500 over the past ninety days following CEO Samarth Kulkarni’s selling 25,000 shares last April 25th., equity research analysts have reissued several “buy” ratings for the stock throughout multiple reports. VNET Group reiterated their positive outlook on Tuesday May 9th; Cantor Fitzgerald initiated coverage on CRISPR Therapeutics on Thursday April 13th giving them an overweight rating along with a price objective of $72 CAD per share; Stocknews.com upgraded shares of CRISPR Therapeutics to a ‘sell’ rating on Thursday May11th; Oppenheimer decreased their price objective from $110 towards $102 but maintained their “buy” rating on Thursday Feb 23rd; finally, Stifel Nicolaus decreased their objective price from $69 to $64.

CRISPR Therapeutics traditionally opens at $61.70 and currently holds a 1-year high of $86.95 and a low of #38.94 with a market capitalization of roughly $4.87 billion and a beta score of 1.71. Although two equity research analysts rated the stock as “sell”, eight have given CRISPR Therapeutics a hold rating and ten have issued a buy recommendation on its shares, with an average rating of “Hold” on Bloomberg accompanied by an average consensus price target set at around $72 CAD per share still suggesting there are positive prospects ahead for the company’s future growth and earnings potential.


Read more here: Source link